Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapies' returned 2 results - Page 1 of 1   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for success   Datamonitor, Dec 2010, Pages: 285 ? - What is the potential for novel therapies, such as Allergan's Botox and Astellas's mirabegron, in the competitive urinary incontinence market? - What will be the impact of key market events Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report   Global Industry Analysts, Inc., Aug 2011, Pages: 279 of overactive bladder therapeutics include constipation, mental confusion, and dry mouth. Drugs offering a novel action mechanism that assists in significantly reducing incontinence episodes and urinary frequency Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network